Effect of Sensory Training on Functional Performance, Balance, Gait in Type 2 Diabetic Individuals With Neuropathy
Launched by AYLIN DEMİR · May 16, 2025
Trial Information
Current as of July 24, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a specific type of training focused on improving foot sensation can help individuals with type 2 diabetes and nerve damage (known as diabetic peripheral neuropathy) improve their balance, walking ability, and overall function. The study will involve 40 participants who are between 35 and 65 years old, have controlled diabetes, and show signs of nerve damage on a simple test. Participants will be divided into two groups: one will receive sensory training for their feet, while the other group will not receive any training during the study but will have the option to do so afterward.
If you decide to participate, you can expect to undergo a few tests at the beginning and end of the study to assess your foot sensation, balance, walking ability, and any fears you may have about movement. The study aims to see if improving foot sensation can lead to better performance in daily activities and a reduction in fear of falling. It’s important to note that certain health conditions, such as severe respiratory issues or other serious complications from diabetes, may exclude you from participating. The study is not yet recruiting, so there will be more information available when it begins.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Being 35-65 years old
- • Being diagnosed with type 2 diabetes
- • Having achieved glycemic control
- • Having given less than 8 correct answers in the Semmes-Weinstein Monofilament test performed with a 5.07 monofilament
- • Getting a Neuropathy Disability Score of 3 and above
- • Being willing to participate in the study
- • Being literate
- Exclusion Criteria:
- • Having a neurological or orthopedic comorbidity
- • Having a respiratory disease such as uncontrolled COPD or asthma
- • Having active lower extremity ulceration
- • Using medications known to affect the postural control system such as benzodiazepines
- • Having nephropathy, retinopathy and diabetic arthritis at a level that may affect mobility in addition to neuropathy
- • Using a walking aid
- • Body Mass Index \>30
- • Having communication problems
- • Not participating in at least 3 consecutive exercise sessions
- • Not participating in more than 30% of each session
About Aylin Demi̇r
Aylin Demir is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and a collaborative approach, Aylin Demir leads the design and implementation of clinical trials that adhere to the highest ethical and regulatory standards. Her expertise in clinical research management and a keen understanding of therapeutic areas enable the efficient execution of trials, fostering partnerships with research institutions and healthcare professionals. Aylin Demir’s vision is to contribute to the development of groundbreaking treatments that address unmet medical needs and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Malatya, Battalgazi, Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported